Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
Crescent Biopharma gains rights to a Kelun-Biotech antibody drug conjugate it plans to test in combination with its lead cancer drug, a bispecific antibody designed to block PD-1 and VEGF. Separately, Crescent raised $185 million in a private placement to support its clinical trial plans.
Alan Murray on improving access for medical transportation.
Cleveland Clinic is expanding its use of Dyania Health’s AI platform across the health system to speed up clinical trial recruitment. The system quickly scans patient records to identify eligible participants, aiming to give more patients access to trials and speed up development timelines for new therapies.
Prioritizing risk-based management, data science, smart automation, standards, and patient optionality are critical for the industry to keep up with market changes. The recent FDA guidance that encourages ‘pragmatic trials’ in specific scenarios is a move in the right direction.
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
AIQ is not just about adopting a new technology. We’re talking about a fundamentally different way of thinking. A shift in what’s possible in clinical research, and a new standard for execution.
By reimagining clinical trials as the initial step in designing a service ecosystem, organizations can accelerate time to delivery and lay the groundwork for successful commercialization.
Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs; the three companies raised $636 million combined.
Understanding how site augmentation services could be leveraged to overcome challenges is not the responsibility of one entity. The most creative and effective solutions arise from collaboration among all stakeholders — sponsors, CROs, service providers, and research sites.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market.
The clinical trial process is complex, long, and always arduous. But the results of the drug development process can be amazing, new, safe, effective, life-changing, and life-enhancing therapies.
This technological shift not only boosts efficiency and profitability for pharmaceutical companies but also speeds up the delivery of innovative therapies to patients.
By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders.
Many great ideas fail because of a fundamental misunderstanding or underestimation of the unique barriers entrenched within healthcare. Here are some key considerations that innovators from non-healthcare backgrounds need to be prepared for.